Quarterly report pursuant to Section 13 or 15(d)

Note 12 - Segment Information

v3.10.0.1
Note 12 - Segment Information
 3 Months Ended
Sep. 30, 2018
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]
Note
12.
Segment Information:
 
The Company's management evaluates segment operating performance based on operating income before certain charges to cost of sales and selling, general and administrative expenses, principally associated with acquisition accounting related to inventory, amortization of acquisition-related intangible assets and other acquisition-related expenses.  The Protein Sciences and Diagnostics and Genomics reportable segments both include consumables, instruments, services and royalty revenue.
 
The following is financial information relating to the Company's reportable segments (in thousands):
 
   
Quarter Ended
  
   
September 30,
  
   
2018
    
2017
  
Net sales:
                
Protein Sciences
   $
126,391
     $
108,113
  
Diagnostics and Genomics
    
36,747
      
36,589
  
Intersegment
    
(168
)
    
(89
)
Consolidated net sales
   $
162,970
     $
144,613
  
Operating income:
                
Protein Sciences
   $
54,614
     $
46,209
  
Diagnostics and Genomics
    
2,536
      
7,279
  
Segment operating income
    
57,150
      
53,488
  
Costs recognized on sale of acquired inventory
    
(935
)
    
(318
)
Amortization of acquisition related intangible assets
    
(14,276
)
    
(11,379
)
Acquisition related expenses
    
(2,631
)
    
(9,533
)
Stock-based compensation
    
(11,565
)
    
(3,795
)
Corporate general, selling, and administrative expenses
    
(1,980
)
    
(2,432
)
Consolidated operating income
   $
25,763
     $
26,031